In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.
M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), S. E. Salmon(University of Arizona), Rita de Giuli(Kantonsspital St. Gallen), William S. Dalton(Texas Oncology), Scott S. Emerson(Cleveland Clinic Lerner College of Medicine)
PubMed
January 1, 1993
Cited by 20
Related Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799